Capped mesoporous silicates
View Patent ↗The invention provides an article comprising, a mesoporous silicate matrix, such as a particle, having one or more pores; and one or more releasable caps obstructing one or more of the pores. The articles are useful as delivery vehicles for encapsulated agents such as therapeutic agents, polynucleotides, polypeptides and the like.
1. An article comprising,
a mesoporous silicate body having one or more pores; and
one or more removable caps obstructing one or more of the pores;
wherein the mesoporous silicate body has a particle size of less than about 750 nm;
wherein one or more caps is a cadmium sulfide nanoparticle; and
wherein the cadmium sulfide nanoparticle is covalently bonded to the mesoporous silicate body through a linking group comprising 2-(propyldisulfanyl)ethylamine.
2. The article of claim 1 wherein the silicate body is a microparticle or a nanoparticle.
3. The article of claim 1 wherein the pores are about 1-50 nm in diameter.
4. The article of claim 1 wherein the pores are less than about 50 nm in size.
5. The article of claim 1 wherein the pores are less than about 40 nm in size.
6. The article of claim 1 wherein the pores are less than about 30 nm in size.
7. An article comprising,
a mesoporous silicate body having one or more pores; and
one or more removable caps obstructing one or more of the pores;
wherein the mesoporous silicate body has a particle size of less than about 750 nm;
wherein one or more caps is a cadmium sulfide nanoparticle; and
wherein the cadmium sulfide nanoparticle is covalently bonded to the mesoporous silicate body through a linking group of formula X-CH 2 CH 2 CH 2 SSCH 2 CH 2 NHC(═O)CH 2 —Y, wherein X is a silicon atom of the mesoporous silicate and Y is a sulfur atom of the cadmium sulfide nanoparticle.
8. An article comprising,
a spherical mesoporous silicate body having one or more pores; and
one or more removable caps obstructing one or more of the pores;
wherein the mesoporous silicate body has a particle size of less than about 750 nm;
wherein one or more caps is a cadmium sulfide nanoparticle; and
wherein the cap is covalently bonded to the mesoporous silicate body through a linking group that comprises a disulfide, wherein the disulfide is a 2-(propyldisulfanyl)-ethylamine group.
9. An article comprising,
a spherical mesoporous silicate body having one or more pores; and
one or more removable caps obstructing one or more of the pores;
wherein the mesoporous silicate body has a particle size of less than about 750 nm;
wherein one or more caps is a cadmium sulfide nanoparticle; and
wherein the cap is covalently bonded to the mesoporous silicate body through a group of formula X—CH 2 CH 2 CH 2 S—SCH 2 CH 2 NHC(═O)CH 2 —Y, wherein X is a silicon atom of the mesoporous silicate and Y is an atom of the cadmium sulfide cap.
10. The article of claim 1 or 2 further comprising an encapsulated agent enclosed in one or more of the pores.
11. The article of claim 10 wherein the encapsulated agent is a bioactive agent.
12. The article of claim 10 wherein the encapsulated agent is therapeutic agent or a diagnostic agent.
13. The article of claim 10 wherein the encapsulated agent is a chemotherapeutic agent, a chelated radionuclide, an immunosuppressive drug, an antiinflammatory agent, an antibacterial agent, an antifungal agent, an antiviral agent, an analgesic agent, a polypeptide, a hormone, a hormonal messenger, a cytokine, an imaging agent, a contrast agent, an enzyme, a vitamin, a cosmetic agent, a nutrient, a gene expression suppressive drug, a neurotransmitter, a RNA molecule, or a DNA molecule.
14. A pharmaceutical composition comprising a particulate article as described in claim 12 and a pharmaceutically acceptable carrier.
15. The composition of claim 14 which is formulated for oral administration, topical administration or for administration by injection.
16. The article of claim 1 wherein the mesoporous silicate body is a sphere having a diameter of less than about 300 nm.
17. The article of claim 1 wherein the mesoporous silicate body is a sphere having a diameter of less than about 200 nm.
18. The article of claim 1 wherein the mesoporous silicate body is a sphere having a diameter of less than about 100 nm.
19. The article of claim 1 wherein the mesoporous silicate body is a sphere having a diameter of greater than about 50 nm.
20. The article of claim 7 wherein the silicate body is a microparticle or a nanoparticle.
21. The article of claim 7 wherein the pores are about 1-50 nm in diameter.
22. The article of claim 7 wherein the pores are less than about 50 nm in size.
23. The article of claim 7 wherein the pores are less than about 40 nm in size.
24. The article of claim 7 wherein the pores are less than about 30 nm in size.
25. The article of claim 8 wherein the silicate body is a microparticle or a nanoparticle.
26. The article of claim 8 wherein the pores are about 1-50 nm in diameter.
27. The article of claim 8 wherein the pores are less than about 50 nm in size.
28. The article of claim 8 wherein the pores are less than about 40 nm in size.
29. The article of claim 8 wherein the pores are less than about 30 nm in size.
30. The article of claim 8 or 9 further comprising an encapsulated agent enclosed in one or more of the pores.
31. The article of claim 30 wherein the encapsulated agent is a bioactive agent.
32. The article of claim 30 wherein the encapsulated agent is therapeutic agent or a diagnostic agent.
33. The article of claim 30 wherein the encapsulated agent is a chemotherapeutic agent, a chelated radionuclide, an immunosuppressive drug, an antiinflammatory agent, an antibacterial agent, an antifungal agent, an antiviral agent, an analgesic agent, a polypeptide, a hormone, a hormonal messenger, a cytokine, an imaging agent, a contrast agent, an enzyme, a vitamin, a cosmetic agent, a nutrient, a gene expression suppressive drug, a neurotransmitter, a RNA molecule, or a DNA molecule.
34. A pharmaceutical composition comprising a particulate article as described in claim 32 and a pharmaceutically acceptable carrier.
35. The composition of claim 34 which is formulated for oral administration, topical administration or for administration by injection.
36. The article of claim 8 wherein the mesoporous silicate body is a sphere having a diameter of less than about 300 nm.
37. The article of claim 8 wherein the mesoporous silicate body is a sphere having a diameter of less than about 200 nm.
38. The article of claim 8 wherein the mesoporous silicate body is a sphere having a diameter of less than about 100 nm.
39. The article of claim 8 wherein the mesoporous silicate body is a sphere having a diameter of greater than about 50 nm.
40. The article of claim 9 wherein the mesoporous silicate body is a sphere having a diameter of less than about 300 nm.
41. The article of claim 9 wherein the mesoporous silicate body is a sphere having a diameter of less than about 200 nm.
42. The article of claim 9 wherein the mesoporous silicate body is a sphere having a diameter of less than about 100 nm.
43. The article of claim 9 wherein the mesoporous silicate body is a sphere having a diameter of greater than about 50 nm.